Polaris was established in 2006. Shortly thereafter it acquired the intellectual property rights to ADI-PEG 20 and several early development stage cancer treatment drugs from Phoenix Pharmacologics, Inc.

The company's management team consists of experienced research scientists and business professionals. Its Scientific Advisory Board brings together decades of scientific, clinical, and business expertise.